The '10 commandments' for the 2025 focused update of the 2019 ESC/EAS guidelines for the management of dyslipidaemias

Guidelines evaluate and summarize available evidence with the aim of assisting health professionals in proposing the best diagnostic or therapeutic approac

YouTube video by MARKUS at HOMe

Esperion (NASDAQ: ESPR) announced that bempedoic acid has received a prestigious Level 1a recommendation in the 2025 European Society of Cardiology (ESC)/European Atherosclerosis Society (EAS) Guidelines for Dyslipidaemias management.The guidelines specifically recommend bempedoic acid as the only non-statin newly recommended treatment for LDL-C lowering and cardiovascular risk reduction. Key recommendations include using bempedoic acid for patients unable to take statins (Class I, Level A/B) and considering its addition to maximum statin doses with/without ezetimibe for high-risk patients (Class IIa, Level C).This recognition supports Esperion's strategic development of oral triple combination therapies, aligning with the guidelines' emphasis on earlier, aggressive combination therapy. The company's portfolio includes NEXLETOL (bempedoic acid), NEXLIZET (bempedoic acid and ezetimibe), and upcoming triple combinations with atorvastatin or rosuvastatin.